Immuno-Oncology and Cell Therapy

Editors Pick Could In Vivo CAR-T Cell Therapy Replace Ex Vivo
Executive Perspectives

Editor's Pick: Could In Vivo CAR-T Cell Therapy Replace Ex Vivo?

Dr Adrian Bot, Capstan Therapeutics, tells us how in vivo CAR-T cell therapy, both through viral and non-viral vectors, could provide patients with a less toxic and more accessible alternative to traditionally manufactured ex vivo CAR-T.
Danny McCarthy Feb 3, 2026 12:00am
Where AI is Reshaping Imaging for Oncology Drug Development

Where AI is Reshaping Imaging for Oncology Drug Development

Feb 2, 2026 12:00am
Women Leadership in Immuno-Oncology Annual Profile Series 2026 Edition

Women Leadership in Immuno-Oncology Annual Profile Series: 2026 Edition

Jan 28, 2026 12:00am
Going After Mismatch Repair Deficiency in Solid Tumors for Powerful Tumor Response

Going After Mismatch Repair Deficiency in Solid Tumors for Powerful Tumor Response

Jan 21, 2026 12:00am
West-China Biotech Collaboration Dynamics

West-China Biotech Collaboration Dynamics

Jan 20, 2026 12:00am
IO Biotech Investor Perspective on Raising Capital Trends in Biotech and Advice for Young Investors

IO Biotech Investor Perspective on Raising Capital Trends in Biotech and Advice for Young Investors

Jan 20, 2026 12:00am